DNLI - Denali Therapeutics

-

$undefined

N/A

(N/A)

Denali Therapeutics NasdaqGS:DNLI Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Location: 161 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.denalitherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.201B

Cash

817.9M

Avg Qtr Burn

-91.39M

Short % of Float

9.27%

Insider Ownership

9.94%

Institutional Own.

94.26%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

BLA

Submission

DNL343 (eIF2B Activator) Details
Amyotrophic lateral sclerosis

Phase 2/3

Data readout

Phase 2b

Data readout

Phase 2

Data readout

DNL758 (CNS-penetrant RIPK1 inhibitor) Details
Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis

Phase 2

Data readout

BIIB122 (DNL151) Details
Parkinson's disease

Phase 2a

Data readout

TAK-594/DNL593 (PTV:PGRN) Details
Frontotemporal dementia with GRN mutations

Phase 1/2

Data readout

DNL126 (ETV:SGSH) Details
Sanfilippo Syndrome

Phase 1/2

Update

Failed

Discontinued